Hepatitis C Virus NS3/4A Protease Inhibitor
5 drugs across 3 manufacturers|0 Generic,5 Brand
The Hepatitis C Virus NS3/4A Protease Inhibitor class contains 5 NDCs from 3 manufacturers (0 generic, 5 brand), at an average NADAC of $390.38 per unit. Every drug, manufacturer, and price in this FDA-defined pharmacologic class is listed below.
Total Drugs
5
0G / 5B
Manufacturers
3
Avg $390.3752/unit
Avg 7d Change
+0.04%
Across 3 drugs with changes
7d Activity
of 5 total drugs
Class Price Trend
Monthly average NADAC price per unit, split by generic and brand
Manufacturer Breakdown
3 manufacturers producing drugs in this therapeutic class
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
VOSEVI 400-100-100 MG TABLET SOFOSBUVIR, VELPATASVIR, and VOXILAPREVIR | $858.6884 per EA | — |
ZEPATIER 50-100 MG TABLET elbasvir and grazoprevir | $634.2375 per EA | — |
MAVYRET 100-40 MG TABLET Glecaprevir and Pibrentasvir | $152.9834 per EA | +0.04% |
MAVYRET 100-40 MG TABLET Glecaprevir and Pibrentasvir | $152.9834 per EA | +0.04% |
MAVYRET 100-40 MG TABLET Glecaprevir and Pibrentasvir | $152.9834 per EA | +0.04% |
Follow this class across the site
These links connect the therapeutic class page to the specific suppliers, markets, and trend surfaces that help users keep exploring.
Top supplier
AbbVie Inc. manufacturer profile
Review the supplier with the strongest product footprint inside this therapeutic class.
Lead market
Glecaprevir and Pibrentasvir market page
Move from the therapeutic class into the molecule that appears most often in this class-specific portfolio.
Trend hub
Latest trend hub
Compare this class against the rest of the weekly NADAC trend surface.
Guide
Understanding NADAC pricing
Use the explainer when you need a plain-English refresher on how these class-level numbers are published and interpreted.
Frequently Asked Questions
How many drugs are in the Hepatitis C Virus NS3/4A Protease Inhibitor class?
The Hepatitis C Virus NS3/4A Protease Inhibitor class contains 5 NDCs from 3 manufacturers — 0 generic and 5 brand products.
What is the average price of Hepatitis C Virus NS3/4A Protease Inhibitor drugs?
The average NADAC for the Hepatitis C Virus NS3/4A Protease Inhibitor class is $390.3752 per unit across 5 NDCs.
Which manufacturers make Hepatitis C Virus NS3/4A Protease Inhibitor drugs?
3 manufacturers make drugs in the Hepatitis C Virus NS3/4A Protease Inhibitor class. Ranked by number of NDCs, the largest are AbbVie Inc. (3), Gilead Sciences, Inc. (1), Merck Sharp & Dohme LLC (1).
How has Hepatitis C Virus NS3/4A Protease Inhibitor pricing changed recently?
Over the past 7 days, 3 NDCs in this class rose and 0 fell, with a class-wide average change of +0.0%.